MassBio Innovation Services
Jan 15, 2015
MassBio Innovation Services
Why you need to invest in MassBio Innovation Services!
10
20
30
40
50 60
40
30
20
10
1995 2000 2005
50
NM
Es
and
Bio
log
ics
Ap
pro
ved R
&D
Sp
end
ing
(US
$ Billio
ns)
R&D expenditures
Approvals
Sources: FDA/CDER, PhRMA, PricewaterhouseCoopers
Note: R&D spending from non-PhRMA companies not available
Despite yearly increases in R&D spending, Despite yearly increases in R&D spending, approvals stagnateapprovals stagnate
Courtesy of Ted Torphy, JNJ presented at MassBio Pharma Days
Pharma’s failure to innovate means biotech Pharma’s failure to innovate means biotech innovation must step upinnovation must step up
Pharma need products Increasingly, biotechs are the major source of new
products
Creating ever larger Big Pharma R&D organizations through mergers and acquisitions has failed to increase productivity and spur innovation
In recent years, over half of new product approvals were for compounds derived from biotech companies
The traditional venture capital model is stressed:
“…number of VCs doing the early and risky stuff is dwindling. We will probably see the number of start-ups in our space dive this year. … we simply have to find new and creative ways to keep early-stage VC alive, and to redefine roles and responsibilities among the inhabitants of the healthcare ecotope, or we will all perish together…”
– Jens Eckstein, TVM Capital
Life sciences innovation is the lifeblood of Life sciences innovation is the lifeblood of biopharmaceuticalsbiopharmaceuticals
Precious resource that should be jealously guarded
Very hard to emulate Lifesciences is a jewel in the crown
Established “Specialty Clusters”
Clu
ster
S
ize
La
rge
EmergingCluster Capability
Sm
all
World-class
SFSF
MAMASDSD
SingaporeSingapore
IndiaIndiaChinaChina
United KingdomUnited
Kingdom
IrelandIreland
SwitzerlandSwitzerland
PhiladelphiaPhiladelphia
RTPRTPCanadaCanada
MadisonMadison
DC / BaltimoreDC / Baltimore
Integrated Clusters
Emerging Clusters
Leading Integrated Clusters
Lagging Integrated Clusters
New partnerships are needed among key New partnerships are needed among key stakeholders to drive innovationstakeholders to drive innovation
Academia and biotech are leading sources of innovative assets, many of which are under-valued and under-resourced
New approaches to traditional venture financing are necessary to create value by investing in early stage opportunities
Without a new business model, the industry cannot meet the demand for innovative new products
Global demand increasing due to an aging population
Growth and shareholder value will suffer
“[Pharma] spends tremendous amounts of cash to buy each other, or to purchase their own outstanding shares to prop up share prices, and I am skeptical that they will have the persistence and vision, the personal engagement, and the relationships to budding or serial entrepreneurs required to drive innovation in the long run”
-Jens Eckstein, TVM Capital
The fount of opportunity for pipeline growth The fount of opportunity for pipeline growth and enabling technology exists with new and enabling technology exists with new start-upsstart-ups
Invest early into your future pipeline
“Find a mechanism in your partnership to do seed investments. Help early-stage ventures find and address the killer issue or experiment as early as possible.”
-Jens Eckstein, TVM Capital
Work with MassBio to cultivate that next generation “killer app”
“There are actually cool technologies laying dormant all over the place…The world is flat but our minds and eyes haven’t figured out how to capture all that global knowledge yet.”
-Lesa Mitchell, Kauffman Foundation
MassBio programs connect talent, MassBio programs connect talent, innovation, and capital through its networkinnovation, and capital through its network.
In 2010, MassBio will launch MassBio Innovation Services (MBIS) increase the efficiency by which technology and
value is exchanged between buyers and sellers.
For you, it means less time travel and money spent searching for opportunities; it means having one place to meet the right people, for the right opportunities, to forge the right collaborations.
The purpose of MBIS is to improve your access to
strategic assets, for license and acquisition.
MassCONNECT
MassBio Innovation Exchange
Pharma Days
Investor Forum
Innovators’ Roundtable
MassCONNECT – MassCONNECT – advise, mentor, and steer advise, mentor, and steer emerging companies arising from the emerging companies arising from the program.program. Participate in identifying, screening, and
selecting cutting edge life science opportunities
Participate in mentoring teams (to position start ups for success) around pre-funded technologies.
Get a “first look” innovative platforms, molecules of interest, and more predictive diagnostics,
Opportunity to later invest and collaborate
MassCONNECT
MassBio Innovation Exchange
Pharma Days
Investor Forum
Innovators’ Roundtable
MassBio Innovation ExchangeMassBio Innovation Exchange – Access and – Access and maximize opportunity assessment for world class IP maximize opportunity assessment for world class IP and leading biotechnology companiesand leading biotechnology companies MassBio is the one point of entry
to over 375 innovative biotechnology companies and world class biomedical institutions.
Portal to potential new product opportunities to complement your pipeline.
true and secure electronic connection between Innovators and bio/pharma companies.
State-of-the-art web-based program will help facilitate communications of your portfolio strategy to Sellers, and improve the overall quality, quantity and speed of commercialization of biotech innovation.
Coupled with Pharma Days, MassCONNECT, and the Investor Forum, the Exchange will leverage the personal interaction of partnering meetings with the secure confidential exchange of information using cutting edge technology.
MassCONNECT
MassBio Innovation Exchange
Pharma Days
Investor Forum
Innovators’ Roundtable
Pharma Days – Pharma Days – Concentrated and focused Concentrated and focused partnering with premiere biotech companies at your partnering with premiere biotech companies at your convenienceconvenience
One-on-one partnering with CEOs and heads of business development
in your therapeutic/diagnostic space.
Present your company’s sourcing
strategy for new licenses and acquisitions to the biotechnology community.
Intimate and unhurried exchange Intimate and unhurried exchange of information.of information.
Obviate the frenzy and “noise” of other major partnering conferences
Our staff will work with you to:
identify, invite and follow up with the contacts you’d like to meet.
Reserve your Pharma Day today as slots are limited to 9 per year, and they are filling up rapidly!
A one to two day unique partnering event that is all about your company and the visibility you get before 120+ of the most innovative biotechnology firms;
Best of all, Pharma Days is right here in Cambridge! No need to travel, take time out of your offices, or waste time trying to find a time to meet.
MassCONNECT
MassBio Innovation Exchange
Pharma Days
Investor Forum
Innovators’ Roundtable
MassBio Investors Forum – MassBio Investors Forum – Aggregates deal makers Aggregates deal makers from all sides at one locationfrom all sides at one location
Capstone to the yearlong Pharma Days program.
Our flagship event is the premiere investment and partnering conference in the Northeast!
This year’s event drew over 500 attendees:
corporate strategics, VCs, pharma executives, disease foundation leaders, and heads of biotechnology companies.
Aggregates financing capital from multiple
streams
Offers a unique opportunity to meet with new biotechnology companies and disease foundations to build therapeutic and diagnostic programs in your organization.
Sponsor the Investor Forum and drive content, give voice to your viewpoint through panel construction and participation, and achieve visibility before potential partners.
MassCONNECT
MassBio Innovation Exchange
Pharma Days
Investor Forum
Innovators’ Roundtable
Innovators Roundtables – Solutions-based Innovators Roundtables – Solutions-based dialogue with leaders in industry and dialogue with leaders in industry and stakeholdersstakeholders
Exclusive roundtable discussions with leading academicians, CEOs, R&D heads, angel investors, venture capitalists.
The objective is to define a set of initiatives, where participants can, directly or through influence, bring the necessary funding to bear to assure that those early stage innovations with the highest potential continue to the clinic, enrich pipelines and improve options for patients.
to devise better collaborative models to expedite
translational therapeutics.
MassCONNECT
MassBio Innovation Exchange
Pharma Days
Investor Forum
Innovators’ Roundtable
Subscribe to MBIS servicesSubscribe to MBIS services
MassBio Innovation Exchange – Access and maximize opportunity assessment for world class IP and leading biotechnology companies ($20,000)
Charter member fee: $20,000 covers cost of software and first year’s annual access fee. Non-Charter Members will pay software and access fees of $60,000 the first year and $20,000 each year thereafter as part of the subscription fee;
MassCONNECT – Get a first look at innovative platforms, therapeutics and diagnostics ($20,000 for Platinum Sponsorship)
Company joins MassCONNECT as a platinum sponsor for $20,000. Five bio/pharma companies will be accepted as platinum sponsors.
Pharma Days – Concentrated and focused partnering with premiere biotech companies at your convenience ($10,000) - slots are limited to 9 per year!
Customize Pharma Days to your specification, including cocktail reception (additional cost of $5000), lunch, and breakfast.
Investors Forum – Aggregates deal makers from all sides at one location and further connections made at Pharma Days ( $25,000)
Company participates on the strategy of the event, planning and steering committee for the 2010 Investor Forum/BioPHARM America conference, a premiere 3 day partnering and investor conference.
Innovators’s Roundtable – Solutions based dialogue with leaders in industry from all stakeholders ($2,500)
MassCONNECT
MassBio Innovation Exchange
Pharma Days
Investor Forum
Innovators’ Roundtable